Companies: 49,246 Total Market Cap: 132441797263938.02

ALTEOGEN

KOSDAQ-196170
Healthcare Biotechnology
Rank #1593
Market Cap 12.05 B
Volume 223,115
Price 226.06
Change (%) 0.63%
Country or region South Korea South Korea

ALTEOGEN's latest marketcap:

12.05 B

As of 05/20/2025, ALTEOGEN's market capitalization has reached $12.05 B. According to our data, ALTEOGEN is the 1593th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 12.05 B
Revenue (ttm) 107.97 M
Net Income (ttm) 88.62 M
Shares Out 53.30 M
EPS (ttm) 1.66
Forward PE 676.85
Ex-Dividend Date n/a
Earnings Date 05/15/2025
Market Cap Chart
Data Updated: 05/20/2025

ALTEOGEN's yearly market capitalization.

ALTEOGEN has seen its market value grow from ₩5.05 T to ₩16.92 T since 2020, representing a total increase of 235.31% and an annual compound growth rate (CAGR) of 31.75%.
Date Market Cap Change (%)
05/20/2025 ₩16.92 T 2.58%
12/30/2024 ₩16.49 T 221.05%
12/28/2023 ₩5.14 T 160.78%
12/29/2022 ₩1.97 T -38.41%
12/30/2021 ₩3.20 T -36.62%
12/30/2020 ₩5.05 T

Company Profile

About ALTEOGEN Inc.

ALTEOGEN Inc. is a biotechnology company specializing in the development of innovative biopharmaceuticals, including long-acting biobetters, proprietary antibody-drug conjugates (ADCs), and antibody biosimilars.

Key Product Pipeline

  • ALT-P1: A long-acting human growth hormone currently in Phase IIa clinical trials.
  • ALT-Q2: A long-acting coagulation factor VII for hemophilia treatment, developed using NexP technology.
  • ALT-P7: A targeted therapy for breast and gastric cancer in Phase I clinical trials.
  • ALT-Q5: An antibody-drug conjugate (ADC) for ovarian cancer, leveraging NexMab ADC technology.
  • ALT-LS2: A subcutaneous formulation of trastuzumab for breast and gastric cancer.

Strategic Alliances

  • Kissei Pharmaceutical: Collaboration on ALT-L9, a biosimilar of Eylea (Aflibercept) in Phase 1 trials.
  • Cristalia: Partnership for ALT-L2, a biosimilar of Herceptin (Trastuzumab) for breast cancer, now in Phase II trials.

Company Background

Founded in 2008, ALTEOGEN Inc. is headquartered in Daejeon, South Korea, and continues to advance its mission of delivering cutting-edge biopharmaceutical solutions.

Frequently Asked Questions

As of 05/20/2025, ALTEOGEN (including the parent company, if applicable) has an estimated market capitalization of $12.05 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.

ALTEOGEN global market capitalization ranking is approximately 1593 as of 05/20/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

Stock Detail

Country or region South Korea
Founded 2008
IPO Date n/a
Employees 145
CEO Soon-Jae Park
Sector Healthcare
Industry Biotechnology
Address 62, Yuseong-daero
Daejeon, 34054
South Korea
Website https://www.alteogen.com
People Also Watch
VRTX
444.31 0.63%
CSL Limited
156.27 0.63%
REGN
605.54 0.63%
KRX-207940
731.22 0.63%